Moderna, Inc.
Moderna develops, manufactures and commercializes mRNA vaccines and therapeutics for the prevention and treatment of disease. Its commercial products are Spikevax and mNEXSPIKE, COVID vaccines, and mRESVIA, an RSV vaccine. Moderna also advances development candidates across infectious disease, oncology and rare disease, including seasonal flu and flu plus COVID vaccines, cancer therapies, and treatments for propionic acidemia and methylmalonic acidemia. It works with partners on development and commercialization, including Merck on intismeran and Recordati on mRNA-3927. Moderna makes money primarily by selling its commercial vaccines. It uses an mRNA platform spanning mRNA science, delivery technologies and manufacturing processes, and operates a global manufacturing network with facilities in the United States, the UK, Canada and Australia. Moderna is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Arbutus Biopharma is suing Moderna over patent infringement related to COVID-19 vaccine technology. The dispute centers on whether the U.S. government or Moderna should pay for the infringement, with potential liabilities of $1.3 billion. The Federal Circuit will hear arguments on November 5.
Moderna's stock hit a new 52-week high of $258.38 on November 4, up 5.11% from its previous peak on October 21. The shares have risen sharply from their $23-$62 range over the past year, attracting momentum-focused funds.
Moderna (MRNA) announced that the WHO recommended its Ebola vaccine, mRNA-1469, for a Phase 2/3 trial in the Democratic Republic of the Congo. The efficacy study, named Tumaini, has begun.
Over the past 7 days, AlphAI's AI scored 29 news stories mentioning MRNA (Moderna, Inc.). Coverage has skewed bullish: 17 bullish, 5 neutral, and 7 bearish.
Recent MRNA coverage spans technology, market movers and earnings.
In the last 30 days, MRNA insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($17.0M). The most active reporter was Hoge Stephen, President, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential liability could pressure Moderna's share price.
The breakout to a fresh 52‑week high may attract momentum‑focused buying.
Positive catalyst as the vaccine moves into late-stage testing.
Positive early trial signals may boost investor sentiment toward Moderna's oncology pipeline.
Trial data could boost expectations for approval, but manufacturing challenges may limit near‑term upside.
AlphAI scores every news story that mentions MRNA with an AI model for sentiment and relevance, and aggregates insider trades from Moderna, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus Biopharma is suing Moderna over patent infringement related to COVID-19 vaccine technology. The dispute centers on whether the U.S. government or Moderna should pay for the infringement, with potential liabilities of $1.3 billion. The Federal Circuit will hear arguments on November 5.
Moderna's stock hit a new 52-week high of $258.38 on November 4, up 5.11% from its previous peak on October 21. The shares have risen sharply from their $23-$62 range over the past year, attracting momentum-focused funds.
Moderna (MRNA) announced that the WHO recommended its Ebola vaccine, mRNA-1469, for a Phase 2/3 trial in the Democratic Republic of the Congo. The efficacy study, named Tumaini, has begun.
Moderna (MRNA) reported initial clinical data from its Phase 1/2 study of mRNA-2808, an experimental treatment for relapsed or refractory multiple myeloma. Four of 11 patients responded, with no serious side effects observed. The company plans to present updated data at the ASH Annual Meeting in December 2026.
Moderna (MRNA) stock has surged over 800% in the past year, driven by optimism around its cancer vaccine, intismeran, developed with Merck (MRK). Clinical trials showed a 42% reduction in melanoma recurrence and death when combined with Merck's Keytruda. However, mass production may be challenging due to its personalized nature, potentially limiting profitability. Analysts project over $5 billion in peak annual sales for melanoma treatment alone, but approval and scalability remain uncertain.
Moderna (MRNA) rose 5% ahead of earnings, Pfizer (PFE) fell 0.8% despite raising its 2026 outlook, and Merck (MRK) dropped 2% after launching a new Phase 3 trial. Moderna's stock is up 685% YTD, while Pfizer and Merck are up 29% and 40% YTD, respectively. Each company's stock movement diverged from recent headlines.
Moderna (MRNA) shares rose 5.7% to $233.42 ahead of its Q3 2026 earnings report on November 6. Analysts expect $888–$891M in sales. Piper Sandler raised its price target to $230, while Goldman Sachs maintained a $137 target. The stock has gained over 650% YTD, driven by positive melanoma vaccine trial results. The broader market also supports growth and biotech stocks.
Personalis (PSNL) announced a $50M investment from Merck (MRK) at $3.56 per share, giving Merck a 16.5% stake. The company also extended its collaboration with Moderna (MRNA) for its ImmunoID NeXT Platform in cancer therapy development.
Moderna (MRNA) is set to report Q3 2026 earnings on Nov 6, with sales and EPS estimates at $888.8M and -$1.37 respectively, both down year-over-year. The company's Earnings ESP is -71.32%, suggesting a potential miss. Key products include COVID-19, flu, and RSV vaccines, with oncology pipeline updates expected. MRNA stock has surged 652% YTD, trading at a premium valuation.
Merck (MRK) and Moderna (MRNA) reported that their experimental personalized cancer vaccine, combined with Merck's Keytruda, reduced melanoma recurrence or death risk by 42% in a Phase 3 trial. Merck's Q3 Keytruda sales reached $8.6B, up 6% YoY, but faces patent expiration in 2028. The companies' shares rose on the news, with Merck up 4% and Moderna's value increasing by $30B in one session.
